(3) Donors less than age 18. 
(4) Donors who do not fulfill the criteria as pheresis donors established by the Puget 
Sound Blood Center (Appendix B). 
6. Evaluation and Counseling of Patient and Donor. 
Patients are referred here for consideration of a marrow transplant. Both patient and donor will 
be completely evaluated. The protocol will be discussed thoroughly with patient, donor and family and 
all known risks to the patient and donor described. What is known about engraftment using PBSC’s and 
what is known about the toxicities of G-CSF will be presented as objectively as possible. In this study 
the donor has to be available for a marrow harvest in case engraftment with PBSC’s is not sustained. 
Consent will be obtained using forms approved by the Institutional Review Board of the Fred 
Hutchinson Cancer Research Center. A summary of the conference will be dictated for the medical 
record detailing what was discussed. 
7. Protocol Registration. 
Patients will be identified in the OPD as suitable for this protocol by the research nurse Kathy 
Lilleby. The patient and the donor will have the protocol discussed by either Dr. Bensinger or Buckner. 
This protocol only concerns the source of hematopoietic precursor cells for transplantation. Patient and 
donor will also be presented with the opportunity to participate in protocol 691 which calls for collecting 
an additional day of PBSC’s for genetic marking with the neomycin gene. The principle investigator on 
protocol 691 is Dr. Shuening. The primary treatment protocol will be assigned by the OPD attending 
and agreed upon by the ward coordinator who will register the patient with Barbara Hardin (667-4718). 
8. Plan of Treatment. 
Day 
G-CSF 
PBSC 
Collections 
Day 
BMT 
1. 
-3. 
2. 
-2. 
3. 
-1. 
4. 
X 
0 
5. 
X 
1. 
X 
2. 
— 
A. G-CSF Administration to the Donor: 
(1) G-CSF will be administered by a subcutaneous injection daily beginning 2-3 days 
prior to day 0 (defined as the day marrow would ordinarily be given). The 
schedule of G-CSF administration and PBSC collections can only be ascertained 
once the treatment regimen has been established by the ward coordinator and 
day 0 identified. The preparative regimen will be appropriate to the patient’s 
disease per established autologous or allogeneic protocols. Once a treatment 
[366] 
Recombinant DNA Research, Volume 16 
